Lymphopoiesis is the process in which B and T cells, and innate lymphoid cells (ILCs)
develop from hematopoietic progenitors that exhibit early lymphoid priming. The branching …

The use of chimeric antigen receptor (CAR) T lymphocytes in the treatment of refractory or
relapsed (R/R) B cell acute lymphoblastic leukemia (B-ALL) has meant a radical change in …

PURPOSE We determined the safety and efficacy of coadministration of CD19-and CD22-
chimeric antigen receptor (CAR) T cells in patients with refractory disease or high-risk …

Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer
immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical …

Optical genome mapping (OGM) is a new genome-wide technology that can reveal both
structural genomic variations (SVs) and copy number variations (CNVs) in a single assay …

Minimal/measurable residual disease (MRD) is the most important independent prognostic
factor for patients with B‐lymphoblastic leukemia (B‐LL). MRD post therapy has been …

Presence of minimal residual disease (MRD), detected by flow cytometry, is an important
prognostic biomarker in the management of B‐cell precursor acute lymphoblastic leukemia …

Simple Summary The improved understanding of acute lymphoblastic leukemia has brought
with it several new therapy strategies as well as novel treatment agents. The aim of our …

CD19 is frequently targeted for immunotherapy in B cell malignancies, which may result in
loss of CD19 expression in leukemic cells as an escape mechanism. Stage 0 hematogones …

Background Relapses frequently occur following CD19-directed chimeric antigen receptor
(CAR) T-cell treatment for relapsed or refractory B-cell acute lymphocytic leukaemia in …